Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer
Wednesday, January 11, 2017 - 12:51
in Health & Medicine
Twenty-seven percent of 50 heavily pretreated patients with stage IV HER2+ breast cancer saw clinical benefit from the drug Tucatinib (ONT-380) , with at least 'stable disease' at 24 or more weeks after the start of treatment.